中国肺癌杂志Issue(11)：706-713,8.DOI:10.3779/j.issn.1009-3419.2015.11.09
抗PD-1/PD-L1单抗治疗肺癌临床研究进展
Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
摘要
Abstract
Recently, the immune checkpoint inhibitors which targetprogrammed death-1 (PD-1)/PD-1 ligand (PD-L1) have made a breakthrough in the treatment of advanced non-small cell lung cancer. Researches on immune check-point inhibitors have been rapidly implemented in various types of lung cancer, such as small cell lung cancer and locally ad-vanced non-small cell lung cancer. hTese inhibitors have been applied in combination with other treatment strategies, including chemotherapy, targeting therapy and radiotherapy. However, there are still many problems to be solved, such as searching for ideal biomarkers, exploring different combination treatment models, and identifying the potential mechanisms of primary or secondary drug resistance. Along with these problems to be successfully solved, the immune checkpoint inhibitors will have broader applications in lung cancer therapy.关键词
免疫检验点/PD-1/PD-L1/单克隆抗体/肺肿瘤Key words
Checkpoint/PD-1/PD-L1/Monoclonal antibody/Lung neoplasms引用本文复制引用
黄志煜,李晖(综述),范云(审校)..抗PD-1/PD-L1单抗治疗肺癌临床研究进展[J].中国肺癌杂志,2015,(11):706-713,8.基金项目
本研究受国家自然科学基金（No.81372263）资助hTis study was supported by the grant from the National Natural Science Foundation of China (No.81372263)(to Yun FAN) （No.81372263）
